216 related articles for article (PubMed ID: 27888804)
1. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide Analogs for Treatment of Ovarian Cancer.
Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
[TBL] [Abstract][Full Text] [Related]
4. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
5. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
[TBL] [Abstract][Full Text] [Related]
6. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
[TBL] [Abstract][Full Text] [Related]
7. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
King ML; Lindberg ME; Stodden GR; Okuda H; Ebers SD; Johnson A; Montag A; Lengyel E; MacLean Ii JA; Hayashi K
Oncogene; 2015 Jun; 34(26):3452-62. PubMed ID: 25174399
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
9. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
11. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
[TBL] [Abstract][Full Text] [Related]
14. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Pan JX; Ding K; Wang CY
Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
[TBL] [Abstract][Full Text] [Related]
15. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
16. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
17. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
18. Girinimbine Inhibits the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β-Catenin Signaling Pathways.
Xin Q; Muer A
Med Sci Monit; 2018 Aug; 24():5480-5487. PubMed ID: 30084434
[TBL] [Abstract][Full Text] [Related]
19. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
